Literature DB >> 25530260

Association between serum levels and pentanucleotide polymorphism in the sex hormone binding globulin gene and cardiovascular risk factors in females with polycystic ovary syndrome.

Dinka Pavicic Baldani1, Lana Skrgatic1, Jasmina Ziva Cerne2, Sasa Kralik Oguic3, Blaz Matija Gersak4, Ksenija Gersak2.   

Abstract

The objective of the present study was to evaluate the influence of TAAAA repeat allele length on the levels of serum sex hormone binding globulin (SHBG) and cardiovascular risk factors in patients with polycystic ovary syndrome (PCOS). The study included 91 females with PCOS and 99 healthy controls. Phenotypic hyperandrogenism, body mass index and waist‑to‑hip ratio (WHR) were recorded. Hormonal profiles, fasting insulin and glucose levels, lipid profiles and C‑reactive protein (CRP) levels were measured. Genotyping of TAAAA repeat polymorphisms in the SHBG gene was performed. No significant difference was found in the frequency and distribution of TAAAA repeat alleles between PCOS patients and controls (P=0.739). In PCOS patients, SHBG levels were inversely correlated with serum C‑reactive protein (CRP) levels (R=-0.489, P<0.001). PCOS patients with long TAAAA repeat alleles had significantly lower serum SHBG and free testosterone levels, yet higher CRP levels than patients with short allele repeats. A multiple linear regression model using the number of TAAAA repeats, waist‑to‑hip ratio, a homeostatic model assessment of insulin resistance and age as independent predictors explained 44.8% of the variability in serum SHBG levels. In this model, TAAAA repeat polymorphism was found to be the only reliable predictor of serum SHBG levels (P<0.001). In conclusion, the TAAAA repeat polymorphism was shown to not be a major determinant of the PCOS status, although it influenced serum SHBG levels in females with PCOS. A strong independent association existed between serum SHBG and CRP levels. CRP is an established risk factor of cardiovascular disease and a marker of low‑grade inflammation, typical of atherogenesis. This may be one of the pathways by which low SHBG levels affect cardiovascular risk.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25530260     DOI: 10.3892/mmr.2014.3117

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  10 in total

1.  Association of rs6259 polymorphism with SHBG levels and Poly Cystic Ovary Syndrome in Indian population: a case control study.

Authors:  Richa Bhatnager; Alka Senwal; Smiti Nanda; Amita S Dang
Journal:  Mol Biol Rep       Date:  2019-02-04       Impact factor: 2.316

Review 2.  Role of sex hormone-binding globulin in the free hormone hypothesis and the relevance of free testosterone in androgen physiology.

Authors:  L Antonio; D Vanderschueren; N Narinx; K David; J Walravens; P Vermeersch; F Claessens; T Fiers; B Lapauw
Journal:  Cell Mol Life Sci       Date:  2022-10-07       Impact factor: 9.207

Review 3.  Polycystic Ovary Syndrome: Important Underrecognised Cardiometabolic Risk Factor in Reproductive-Age Women.

Authors:  Dinka Pavicic Baldani; Lana Skrgatic; Roya Ougouag
Journal:  Int J Endocrinol       Date:  2015-06-01       Impact factor: 3.257

4.  Parabolic relationship between sex-specific serum high sensitive C reactive protein and non-alcoholic fatty liver disease in Chinese adults: a large population-based study.

Authors:  Li-Ren Wang; Wen-Yue Liu; Sheng-Jie Wu; Gui-Qi Zhu; Yi-Qian Lin; Martin Braddock; Dong-Chu Zhang; Ming-Hua Zheng
Journal:  Oncotarget       Date:  2016-03-22

5.  Age-dependent endocrine disorders involved in the pathogenesis of refractory acne in women.

Authors:  Simona Ianoşi; Gabriel Ianoşi; Daniela Neagoe; Oana Ionescu; Ovidiu Zlatian; Anca Oana Docea; Corin Badiu; Maria Sifaki; Dimitris Tsoukalas; Aristidis M Tsatsakis; Demetrios A Spandidos; Daniela Călina
Journal:  Mol Med Rep       Date:  2016-11-04       Impact factor: 2.952

6.  Salivary testosterone measurement in women with and without polycystic ovary syndrome.

Authors:  Thozhukat Sathyapalan; Ahmed Al-Qaissi; Eric S Kilpatrick; Soha R Dargham; Joanne Adaway; Brian Keevil; Stephen L Atkin
Journal:  Sci Rep       Date:  2017-06-15       Impact factor: 4.379

Review 7.  Genetic Variants Associated with Hyperandrogenemia in PCOS Pathophysiology.

Authors:  Roshan Dadachanji; Nuzhat Shaikh; Srabani Mukherjee
Journal:  Genet Res Int       Date:  2018-02-18

Review 8.  Cardiometabolic risk in polycystic ovary syndrome.

Authors:  Katica Bajuk Studen; Marija Pfeifer
Journal:  Endocr Connect       Date:  2018-05-29       Impact factor: 3.335

Review 9.  The role of polymorphism in various potential genes on polycystic ovary syndrome susceptibility and pathogenesis.

Authors:  Hiral Chaudhary; Jalpa Patel; Nayan K Jain; Rushikesh Joshi
Journal:  J Ovarian Res       Date:  2021-09-26       Impact factor: 4.234

Review 10.  Classic and Novel Sex Hormone Binding Globulin Effects on the Cardiovascular System in Men.

Authors:  Carla Basualto-Alarcón; Paola Llanos; Gerardo García-Rivas; Mayarling Francisca Troncoso; Daniel Lagos; Genaro Barrientos; Manuel Estrada
Journal:  Int J Endocrinol       Date:  2021-07-21       Impact factor: 2.803

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.